Cannabis Use Disorder Treatment Market

Cannabis Use Disorder Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Cannabis Use Disorder Treatment Market

• Demand and Growth Drivers
  • Rising disease prevalence and improved diagnostic capabilities are likely to support demand for cannabis use disorder treatment solutions as healthcare systems focus on earlier intervention and evidence-based protocols.
  • Regulatory approvals for newer therapeutic agents are expected to expand the addressable patient population and create procurement opportunities across hospital and specialty clinic channels.
  • Increasing healthcare expenditure in Asia and Middle East regions is expected to support adoption of advanced treatment options during the forecast period.
• Product and Segment View
  • Marijuana is likely to remain a leading type segment with 44.6% share, supported by demand from hospital-based treatment protocols.
  • Counselling & Behavioral Therapy is likely to lead the treatment segment with 39.8% share, reflecting institutional procurement patterns.
  • Emerging product categories and niche applications are expected to gain share incrementally as formulation technology and distribution access improve.
• Geography and Competitive Outlook
  • USA is likely to remain a key market owing to advanced healthcare infrastructure and high treatment adoption rates.
  • EU is likely to sustain demand on account of expanding healthcare access and regulatory modernization.
  • Companies that can combine clinical evidence with broad distribution access are likely to gain traction during the forecast period.
• Analyst Opinion
  • The Cannabis Use Disorder Treatment market is evolving from a treatment-driven category into a structured therapeutic segment with clear commercial trajectories.
  • Adoption is being shaped by clinical outcomes data and reimbursement dynamics.
  • The market is also benefiting from increased attention to disease management protocols and preventive care strategies.
  • Demand is further supported by the need for solutions that balance clinical efficacy, patient compliance, and cost management across diverse healthcare settings.

Key Takeaways, Market Size, and Forecast

• The Cannabis Use Disorder Treatment market was valued at USD 1.70 billion in 2025.
• By 2036, the Cannabis Use Disorder Treatment Market is expected to be worth USD 2.82 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 4.7%.
• The market is projected to create an incremental opportunity of USD 1.04 billion between 2026 and 2036.
• In 2026, Marijuana is expected to account for 44.6% of the type segment, driven by demand for first-line treatment protocols.
• USA (5.1%) and EU (4.8%) are two of the fastest growing markets in the world.

Cannabis Use Disorder Treatment Market Definition

The cannabis use disorder treatment market encompasses pharmaceutical products, diagnostic tools, and therapeutic interventions that address the core requirements of type applications across treatment, and related end-use categories. The market covers products segmented by type, treatment, end user, delivery channel, spanning the forecast period from 2026 to 2036.

Cannabis Use Disorder Treatment Market Inclusions

Market scope encompasses all commercially relevant cannabis use disorder treatment products categorized by Type, Treatment, End User, Delivery Channel. The revenue scope covers the period from 2026 to 2036 across North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Cannabis Use Disorder Treatment Market Exclusions

The scope does not include over-the-counter supplements without regulatory approval, general wellness products not specific to the indicated condition, or devices and equipment used solely for diagnostic purposes without therapeutic function.

Cannabis Use Disorder Treatment Market Research Methodology

• Primary Research: Pharmaceutical distributors in important markets, procurement officers at hospital networks, and clinical specialists were interviewed by FMI analysts.
• Desk research: Integrated information from manufacturer disclosures, clinical trial registries, and regulatory filings.
• Market sizing and forecasting: bottom-up aggregation with regional adoption curves across category, treatment, end user, and delivery channel categories.
• Data validation: Quarterly cross-checked with manufacturer filings and worldwide health databases.

Why is the Cannabis Use Disorder Treatment Market Growing?

• In hospital and specialized clinic settings, there is a structured need for evidence-based therapeutic goods due to rising illness burden and increased screening rates.
• Due to its sophisticated healthcare system and growing access to treatment, the USA has the highest growth rate (5.1%).
• Volume growth is being supported by regulatory modernization in several places, which is speeding up the time it takes for innovative therapeutic choices to reach the market.

The market for cannabis use disorder therapy is growing steadily thanks to structural demand drivers that are unlikely to change over the course of the forecast period. Evidence-based treatment protocols are receiving more funding from healthcare systems around the world, and payer systems are starting to cover a wider range of therapy alternatives in this category.

At 44.6%, marijuana has the most share of the type sector. This is a reflection of physician prescribing practices and established clinical standards that support this therapeutic approach as a first-line intervention.

Structural growth variables include policy changes pertaining to treatment recommendations, antimicrobial stewardship, and reimbursement systems. The addressable market for compliant therapeutic items grows as regulatory agencies in the USA, EU, and Asia-Pacific update clinical standards.

Market Segmentation Analysis

• The cannabis use disorder treatment market is segmented across 4 primary dimensions: Type, Treatment, End User, Delivery Channel.
• Marijuana holds 44.6% of the type segment, reflecting its position as the primary therapeutic category.
• Counselling & Behavioral Therapy leads the treatment segment with 39.8% share, reflecting institutional procurement concentration.

The market for cannabis use disorder treatment is organized across product, end-use, and channel dimensions. Segmentation by type includes Marijuana, Tobacco/Nicotine and Vaping, Alcohol, Synthetic Cannabinoids, Others. By treatment, the market includes Counselling & Behavioral Therapy, Detoxification, Medication, Support Group.

Insights into the Marijuana Type Segment

It is anticipated that marijuana will make up 44.6% of the type category in 2026. This therapeutic category is the default option in the majority of treatment protocols due to its well-established clinical data, widespread regulatory approval, and physician familiarity.

Newer formulation techniques are anticipated to enhance patient compliance and clinical outcomes in this segment as treatment methods continue to change. Volume growth is probably going to be sustained by the development of treatment availability in emerging markets.

Insights into the Counselling & Behavioral Therapy Treatment Segment

Counselling & Behavioral Therapy accounts for 39.8% of the treatment segment. This channel benefits from concentrated purchasing authority, standardized procurement processes, and the clinical infrastructure needed to support treatment administration.

Cannabis Use Disorder Treatment Market Drivers, Restraints, and Opportunities

• Rising disease prevalence and evolving treatment guidelines are creating structured demand for therapeutic products that meet evidence-based clinical standards.
• Higher development and manufacturing costs relative to generic alternatives limit adoption in price-sensitive healthcare systems, concentrating growth in reimbursed and premium segments.
• Expansion of reimbursement coverage and guideline inclusion across emerging markets is expected to accelerate adoption during the forecast period.

The cannabis use disorder treatment market is shaped by a balance of demand-side growth factors and supply-side constraints. Clinical evidence continues to support market expansion, while cost management and access challenges moderate the pace of adoption in certain geographies.

Evolving Treatment Protocols and Clinical Guidelines

Demand reflects the ongoing evolution of clinical guidelines toward evidence-based treatment selection. As regulatory bodies update standard-of-care protocols, the addressable market for compliant products expands.

Cost and Access Constraints

Adoption is moderated by the cost differential between newer therapeutic options and established generic alternatives. Reimbursement dynamics and formulary inclusion decisions remain key determinants of market penetration.

Emerging Market Healthcare Expansion

Growth reflects increasing healthcare infrastructure investment across Asia, Latin America, and the Middle East. As hospital capacity and specialist access improve, treatment adoption rates in these regions are expected to converge toward developed market levels.

Analysis of Cannabis Use Disorder Treatment Market By Key Countries

Country	CAGR
USA	5.1%
UK	4.5%
EU	4.8%
Japan	3.5%
South Korea	4.2%

• USA is in first place with a 5.1% CAGR, reflecting advanced healthcare infrastructure and high treatment penetration.
• EU at 4.8% shows strong demand because of expanding treatment access and regulatory modernization.
• UK (4.5%) and South Korea (4.2%) sustain growth through clinical adoption and healthcare system investments.
• Japan at 3.5% shows that healthcare modernization is expanding the treatment-addressable population.

The global cannabis use disorder treatment market is expected to grow at a rate of 4.7% per year from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.

Demand Outlook for Cannabis Use Disorder Treatment Market in USA

The USA will grow by 5.1% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.

• Treatment protocol adoption supports procurement through hospital and specialty channels.
• Reimbursement expansion and formulary updates accelerate patient access.
• Clinical research investment supports development of next-generation treatment options.

Future Outlook for Cannabis Use Disorder Treatment Market in the United Kingdom

The UK will grow by 4.5% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.

• Treatment protocol adoption supports procurement through hospital and specialty channels.
• Reimbursement expansion and formulary updates accelerate patient access.
• Clinical research investment supports development of next-generation treatment options.

Opportunity Analysis of Cannabis Use Disorder Treatment Market in the European Union

The European Union will grow by 4.8% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.

• Treatment protocol adoption supports procurement through hospital and specialty channels.
• Reimbursement expansion and formulary updates accelerate patient access.
• Clinical research investment supports development of next-generation treatment options.

In-depth Analysis of Cannabis Use Disorder Treatment Market in Japan

Japan will grow by 3.5% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.

• Treatment protocol adoption supports procurement through hospital and specialty channels.
• Reimbursement expansion and formulary updates accelerate patient access.
• Clinical research investment supports development of next-generation treatment options.

Sales Analysis of Cannabis Use Disorder Treatment Market in South Korea

South Korea will grow by 4.2% through 2036. This is supported by established healthcare infrastructure, clinical guideline adoption, and expanding treatment access.

• Treatment protocol adoption supports procurement through hospital and specialty channels.
• Reimbursement expansion and formulary updates accelerate patient access.
• Clinical research investment supports development of next-generation treatment options.

Competitive Landscape and Strategic Positioning

• Indivior PLC is the leader in the market with approximately 20.1% share, supported by broad product portfolio, global distribution, and clinical evidence base.
• Zynerba Pharmaceuticals, Pfizer Inc., and GW Pharmaceuticals (Jazz Pharmaceuticals) offer competitive product ranges that address diverse therapeutic needs and institutional procurement requirements.
• New entrants are focusing on specialized applications and niche market segments where clinical differentiation and targeted therapeutic approaches create competitive advantage.

Indivior PLC leads the market through a combination of clinical evidence, regulatory approvals, and distribution access across major healthcare systems. The competitive landscape is fragmented, with established players competing on clinical outcomes, pricing, and market access.

Barriers to entry include regulatory approval timelines, clinical trial investment requirements, and established physician prescribing relationships. Strategic priorities include expanding treatment access, strengthening clinical evidence, and improving cost competitiveness.

Key Companies in the Cannabis Use Disorder Treatment Market

Key global companies leading the cannabis use disorder treatment market include:

• Indivior PLC, Zynerba Pharmaceuticals, Pfizer Inc., GW Pharmaceuticals (Jazz Pharmaceuticals) all have strong clinical portfolios, regulatory approvals, and distribution infrastructure across key markets.
• Adial Pharmaceuticals, Omeros Corporation, BioCorRx Inc. have established regional strength through focused therapeutic expertise and local market knowledge.
• Alkermes PLC, Pear Therapeutics, Braeburn Pharmaceuticals are emerging players that have gained recognition through specialized therapeutic approaches and novel formulation technologies.

Competitive Benchmarking: Cannabis Use Disorder Treatment Market

Company	Product Portfolio	Clinical Evidence	Distribution Reach	Geographic Footprint
Indivior PLC	High	Strong	Strong	Global
Zynerba Pharmaceuticals	High	Strong	Strong	Global
Pfizer Inc.	High	Strong	Strong	Global
GW Pharmaceuticals (Jazz Pharmaceuticals)	Medium	Medium	Moderate	Regional
Adial Pharmaceuticals	Medium	Medium	Moderate	Regional
Omeros Corporation	Medium	Medium	Moderate	Regional
BioCorRx Inc.	Medium	Medium	Low	Emerging
Alkermes PLC	Medium	Medium	Low	Emerging
Pear Therapeutics	Medium	Medium	Low	Emerging
Braeburn Pharmaceuticals	Medium	Medium	Low	Emerging

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Cannabis Use Disorder Treatment Market

• In 2025, the Cannabis Use Disorder (CUD) treatment pipeline remained in the clinical stage, with companies such as Indivior PLC and Aelis Farma progressing investigational therapies, including CB1 receptor modulators, although late-stage trials such as AEF0117 reported mixed or unfavorable efficacy outcomes.
• In 2025, clinical research activity in Cannabis Use Disorder treatment continued to focus on novel pharmacological approaches and behavioral therapies, reflecting the absence of approved drug therapies and the ongoing need for effective treatment options.

Key Players in the Cannabis Use Disorder Treatment Market

Major Global Players

• Indivior PLC
• Zynerba Pharmaceuticals
• Pfizer Inc.
• GW Pharmaceuticals (Jazz Pharmaceuticals)
• Adial Pharmaceuticals
• Omeros Corporation
• BioCorRx Inc.

Emerging Players/Startups

• Alkermes PLC
• Pear Therapeutics
• Braeburn Pharmaceuticals

Report Scope and Coverage

Quantitative Units	USD 1.78 billion to USD 2.82 billion, at a CAGR of 4.7%
Market Definition	The cannabis use disorder treatment market encompasses pharmaceutical products and therapeutic solutions across type, treatment, end user, delivery channel categories.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, EU, Japan, South Korea, 30 plus countries
Key Companies Profiled	Indivior PLC, Zynerba Pharmaceuticals, Pfizer Inc., GW Pharmaceuticals (Jazz Pharmaceuticals), Adial Pharmaceuticals, Omeros Corporation, BioCorRx Inc., Alkermes PLC, Pear Therapeutics, Braeburn Pharmaceuticals
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Segmentation

Cannabis Use Disorder Treatment Market Market Segmented by Type:

• Marijuana
• Tobacco/Nicotine and Vaping
• Alcohol
• Synthetic Cannabinoids
• Others

Cannabis Use Disorder Treatment Market Market Segmented by Treatment:

• Counselling & Behavioral Therapy
• Detoxification
• Medication
• Support Group

Cannabis Use Disorder Treatment Market Market Segmented by End User:

• Rehabilitation Centers
• Hospitals and Clinics
• Others

Cannabis Use Disorder Treatment Market Market Segmented by Delivery Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacy Platforms
• Digital Health Therapy Platforms

Cannabis Use Disorder Treatment Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025). Global Health Observatory Data Repository. WHO.
• USA Food and Drug Administration. (2025). FDA Drug Approval Reports. FDA.
• European Medicines Agency. (2025). EMA Annual Report on Medicinal Products. EMA.
• International Pharmaceutical Federation. (2025). Global Pharmaceutical Market Report. FIP.
• National Institutes of Health. (2025). NIH Research Portfolio Online Reporting Tools. NIH.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the size of the market and revenue from 2026 to 2036.
• Segmentation by type, treatment, end user, delivery channel.
• Insights about more than 30 markets in the region.
• Analysis of therapeutic approaches, clinical adoption, and regulatory dynamics.
• Assessment of the competitive landscape.
• Finding investment opportunities across therapeutic categories and geographic markets.
• Keeping track of the supply chain.
• Delivery of data in PDF and Excel formats.